In the ever-evolving landscape of biopharmaceuticals, companies face the immense challenge of managing regulated data and documents, which has become more complex due to the surge in global regulations. The increasing necessity for a unified Regulatory Information Management (RIM) solution that
October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
Recent developments and analyst perspectives have spotlighted Arbutus Biopharma (NASDAQ: ABUS), indicating a promising growth trajectory for this biopharmaceutical company. Chardan Capital's recent decision to raise its target price for Arbutus Biopharma from $4.00 to $4.50 signifies a potential
The biopharma industry in the United States continues to thrive, driven by innovation, substantial funding, and strategic collaborations. As we look ahead to 2024, certain regions stand out as leading hubs for biopharma activity. The evolution of these hubs is fueled by various factors, including
The biotechnology sector witnesses another strategic maneuver as private equity firms GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices for $1.1 billion. Avid, an influential contract development and manufacturing organization (CDMO), specializes in
Rallybio, a small biotech firm, is on a mission to develop treatments for rare diseases, with a particular focus on fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare but potentially fatal disease results from platelet incompatibility between pregnant mothers and their unborn
